Makan Delrahim, the chief of the Justice Department’s Antitrust Division, is departing on January 19, the day before Joe Biden’s inauguration.
Delrahim submitted his resignation to Donald Trump on Wednesday, January 13, in a letter in which he outlined the accomplishments of the Division during his tenure. He cited an effort to review the Division’s 1,200 consent decrees, which led to the termination of 850 of them, including the Paramount consent decrees. He also cited the launch of a major antitrust lawsuit against Google and an investigation of major tech platforms.
“During my tenure as Assistant Attorney General, the Division successfully enforced the competition laws and implemented transformative policy and organizational initiatives that will bear fruit for both American consumers and entrepreneurs for years to come,” Delrahim wrote in the letter.
During his tenure, Delrahim also launched a review of the consent decrees that govern music licensing, and held a public workshop on the issue.
Before he was confirmed as chief of the Antitrust Division, Delrahim was in the White House counsel’s office, working on the confirmation of Neil Gorsuch to the Supreme Court. Before joining the administration, he was in private practice in Los Angeles at Brownstein Hyatt Farber Schreck.
Biden, who has nominated Merrick Garland as the next US Attorney General, has yet to announce a nominee to lead the Antitrust Division.
Makam Delrahim made his resignation letter public via LinkedIn.
Featured News
Meta Begins Defense After FTC Concludes Case in Landmark Antitrust Trial
May 15, 2025 by
CPI
UK Data Bill Still No Closer to Passage As Parliamentary ‘Ping-Pong’ Drags On
May 15, 2025 by
CPI
Regeneron Pharmaceuticals Awarded $271.2M in Damages Against Amgen
May 15, 2025 by
CPI
FTC Chair Proposes 15% Staff Reduction Amid Budget Constraints
May 15, 2025 by
CPI
UK Urges Antitrust Watchdog to Prioritize Growth and Clarity in Business Regulation
May 15, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Healthcare Antitrust
May 14, 2025 by
CPI
Healthcare & Antitrust: What to Expect in the New Trump Administration
May 14, 2025 by
Nana Wilberforce, John W O'Toole & Sarah Pugh
Patent Gaming and Disparagement: Commission Fines Teva For Improperly Protecting Its Blockbuster Medicine
May 14, 2025 by
Blaž Višnar, Boris Andrejaš, Apostolos Baltzopoulos, Rieke Kaup, Laura Nistor & Gianluca Vassallo
Strategic Alliances in the Pharma Sector: An EU Competition Law Perspective
May 14, 2025 by
Christian Ritz & Benedikt Weiss
Monopsony Power in the Hospital Labor Market
May 14, 2025 by
Kevin E. Pflum & Christian Salas